AwardTape · Defense awards · Research and development · Health R&D · W81XWH20C0100
W81XWH20C0100: -$41K definitive contract to Teva Pharmaceuticals USA, Inc
Teva Pharmaceuticals USA, Inc holds a definitive contract from Defense Health Agency with -$41K obligated since Oct 2023 and $929K obligated over its life, against a ceiling of $970K. Latest action Jan 22, 2025.
Adenovirus vaccine efficiency study.
| PIID | W81XWH20C0100 |
|---|---|
| Type | definitive contract |
| Company | Teva Pharmaceuticals USA, Inc |
| Agency | Defense Health Agency |
| Contracting office | ARMY MED RES ACQ ACTIVITY |
| Category | Research and development · Health R&D |
| PSC | AN95 R&D- MEDICAL: OTHER (OPERATIONAL SYSTEMS DEVELOPMENT) |
| NAICS | 325412 PHARMACEUTICAL PREPARATION MANUFACTURING |
| Obligated since Oct 2023 | -$41K |
| Total obligated (lifetime) | $929K |
| Ceiling (base and all options) | $970K |
| Base date | Aug 5, 2020 |
| Latest action | Jan 22, 2025 |
| End date | Aug 4, 2021 |
| Actions since Oct 2023 | 1 |
| Pricing | Firm fixed price |
| Competition | Not competed |
| Place of performance | PA |
| Source | USAspending.gov record |
| Reporting lag | DoD 90 days |
Source: USAspending.gov prime award data (FPDS), DoD and DHS contracts, orders and IDVs with any action since Oct 1, 2023. Obligated FY2024+ sums the obligations on those actions; total obligated is the award's lifetime figure. DoD contract actions publish on USAspending about 90 days after signing (DFARS PGI 204.6), so the latest DoD actions here trail the calendar by about 3 months. Place of performance shows the state only.
Terminal: alerts on new orders and modifications to this contract, and CSV export.
7 days free for first-time subscribers, then $49/mo. Card required. Cancel before day 8 and you pay nothing.
Start free trial